| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Best selling author and food blogger, Karlynn Johnston provides you with tried, tested and true recipes from her prairie kitchen.
Equisolve is a digital agency that provides website development and ongoing website management services to public companies. They have a proprietary software platform designed specifically to manage the entire digital presence of a public company inclu...
We’re building artificial intelligence capable of driving in any urban environment, anywhere in the world.
Consumer Fusion is a reputation management software and solution that specializes in removing illegitimate reviews from review sites. They provide an all-in-one solution to consolidate and simplify everything about monitoring your business online, comb...